Capmatinib
Brand: Tabrecta (global)
Anticancer
MET inhibitor
Pharmacokinetics
| Half-life | 6.5 hours |
| Tmax | 2 h |
| Protein Binding | 96 % |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Used only in MET exon14 skipping mutation NSCLC; avoid strong CYP3A inhibitors/inducers. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Peripheral edema, nausea, fatigue, photosensitivity, ILD/pneumonitis
Contraindications:
Severe ILD history
Precautions:
Monitor for respiratory symptoms; sun protection advised due to photosensitivity.